ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.
Date | Title & Description | Contributors |
---|---|---|
2024-10-22 |
Reducing the ALS Diagnostic Delay: The Impacts of a Rapid Access Clinic Guest: Kelly Gwathmey, MD ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an... |
|
2024-09-30 |
How CRC Screenings Could Help Reduce Colonoscopy Backlog: A DDW Poster Host: Jennifer Caudle, DO Guest: A. Mark Fendrick, MD Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Dis... |
|
2024-07-09 |
Current Updates in Brain Imaging and Neurodegenerative Diseases Guest: Phillip H. Kuo, MD, PhD One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the b... |
|
2024-07-01 | Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressi... | |
2024-07-01 |
Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals in mCRPC Guest: Geoffrey B. Johnson, M.D., Ph.D. When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things... |
|
2024-06-28 | Guest: Brianna Cagle The Discovery Team at Perspective has developed a compound, called PSV-359, which is a cyclic peptide radiopharmaceutical. It targets a protein, called fibroblast activation protein (FAP), which is a pan-cancer target and... | |
2024-06-28 | Guest: Chi Liu, PhD The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more abou... | |
2024-06-28 | Guest: Geoffrey B. Johnson, M.D., Ph.D. Clinicians are hopeful that theranostics could help treat patients as soon as they go metastatic or even before surgery to try to affect their therapy and possibly get them to avoid having to take toxic... | |
2024-06-28 | Guest: Joyita Dutta The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what’s on the AI horizon and the challenges tha... | |
2024-06-20 |
A Unique Look at the Current and Future Directions of Cancer Vaccines Guest: Lillian Siu, MD, FRCPC Since cancer vaccines have been of interest to oncologists for decades, they’ve been trying to figure out how to prime or stimulate the immune system to attack cancer, and until the last few years, cancer vaccine... |